RecruitingACTRN12622000006741

PLATIPUS Trial: comparison of different pain relief strategies in haemorrhoid banding

Local anaesthetic infiltration after rubber band ligation of rectal haemorrhoids: study protocol for a three-arm, double-blind randomised controlled trial (PLATIPUS trial)


Sponsor

Mr David Proud

Enrollment

120 participants

Start Date

Apr 11, 2022

Study Type

Interventional

Conditions

Summary

Haemorrhoids are enlarged veins in the anus or lower rectum, which can cause bleeding, itching, pain and prolapse outside of the anal canal. The disease is commonly managed using rubber band ligation (RBL), where a band is placed around the base of the haemorrhoid, preventing blood flow to the haemorrhoid and causing it to fall off and pass through the anal canal. The most common complication of RBL is pain. Currently, surgeons vary widely in their approach to preventing pain in these patients, owing to a lack of quality evidence supporting one strategy over another. Surgeons may inject local anaesthetic at the site where the band is placed, or use it to block the nerve supplying the anus and lower rectum. Some patients receive no local anaesthetic, and rely on standard postoperative medications such as paracetamol, anti-inflammatories, and opioids. There is a need for quality research to determine the best strategy for pain management in patients undergoing this common procedure. In our study, participants undergoing RBL will be randomly assigned to receive either local anaesthetic at the banding site, a nerve block, or standard postoperative medications only. These pain management strategies are all routinely used in practice and are safe procedures common in many operations. At several timepoints following the procedure, participants will be asked to report their pain on a scale (up until 2 weeks post procedure). Participants’ use of pain medications in recovery; the time taken for participants to be discharged after their procedure; participant satisfaction with their procedure; the time it takes for participants to return to work after their procedure; and procedure associated complications, will also be recorded. These outcomes will then be used to determine which strategy is best for managing pain in patients undergoing RBL. We hypothesise that both pudendal nerve block and submucosal infiltration of local anaesthetic will be superior to no local anaesthetic for post-procedural pain management.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

Haemorrhoids — swollen veins around the anus — are very common and can cause discomfort, bleeding, and prolapse. Rubber band ligation (RBL) is a simple office-based procedure that cuts off blood supply to the haemorrhoid using a small rubber band. It is very effective, but pain in the hours and days afterwards is a frequent complaint. Currently, surgeons have no strong evidence to guide their choice of pain management strategy, and practice varies widely. The PLATIPUS trial randomly assigns patients undergoing RBL to one of three pain management approaches: a local anaesthetic injected at the banding site, a nerve block to the pudendal nerve (which supplies the anus), or standard post-procedure medications only (paracetamol and anti-inflammatories). Pain scores and medication use will be recorded over the two weeks following the procedure. You may be eligible if you are 18 or older and have consented to have rubber band ligation for haemorrhoids. People with a previous reaction to the local anaesthetics used, additional anorectal conditions like Crohn's disease or an anal fissure, or who are having RBL alongside a major additional procedure are not eligible.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

This is a three-arm trial comparing submucosal local anaesthetic (LA) infiltration, pudendal nerve block (PNB) and standard care for analgesia in haemorrhoid banding. Participants in the submucosa

This is a three-arm trial comparing submucosal local anaesthetic (LA) infiltration, pudendal nerve block (PNB) and standard care for analgesia in haemorrhoid banding. Participants in the submucosal LA group will receive 1-2 mL of 0.5% bupivacaine with adrenaline (1:200,000) 2.5 mg/mL injected in the submucosal plane just proximal to the placement of the rubber band, intra-procedure, immediately prior to placement of the band. Participants in the PNB group will receive 20mL ropivacaine 1% 10mg/mL injected at the pudendal nerve on the ipsilateral side of the haemorrhoid to be banded, administered using anatomic landmarks, intra-procedure, immediately prior to placement of the band (if haemorrhoid disease is bilateral, then the block will be administered bilaterally). To standardise technique, the nerve block will be administered with the aid of an instructional video, which will be distributed to all participating proceduralists. All proceduralists will be consultant surgeons experienced in the administration of local anaesthetic in colorectal procedures. The rubber band ligation procedure typically takes 5-10 minutes, depending on the number of haemorrhoids to be banded and the severity of the disease. Participants' operation reports and/or medical records will be reviewed to monitor adherence to the administration of the anaesthetic agent - all anaesthetic techniques used in any procedure are routinely documented in medical records. Both these interventions are routinely used at the participating study sites in RBL procedures. The decision to opt for one analgesic strategy over another for an isolated RBL procedure in the population eligible for this study is proceduralist dependent; therein lies the clinical equipoise for this study. Accordingly, this trial does not involve the use of unapproved therapeutic goods or procedures.


Locations(1)

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12622000006741


Related Trials